4,4'-thiodiphenol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 17570 |
| CHEMBL ID | 3183502 |
| CHEBI ID | 38957 |
| SCHEMBL ID | 29726 |
| MeSH ID | M0190103 |
| Synonym |
|---|
| 4,4'-thiobis-phenol |
| AC-16455 |
| BIDD:ER0084 |
| p,p'-dihydroxydiphenyl sulfide |
| nsc203030 |
| sulfide, bis(4-hydroxyphenyl) |
| phenol,4'-thiobis- |
| 4,4'-thiodiphenol |
| 4,4'-dihydroxydiphenyl sulfide |
| 4,4'-dihydroxydiphenylsulfide |
| bis(4-hydroxyphenyl) sulfide |
| 4,4-dihydroxydiphenylsulfide |
| nsc-203030 |
| 4,4'-thiobisphenol |
| 4,4'-thio-diphenol |
| 4,4'-dioxydiphenyl sulfide |
| thiobisphenol |
| phenol,4'-thiodi- |
| 2664-63-3 |
| bis(p-hydroxhphenyl) sulfide |
| 4,4-thiodiphenol |
| phenol, 4,4'-thiobis- |
| phenol, 4,4'-thiodi- |
| nsc 203030 |
| 4,4'-dioxydiphenylsulfide |
| einecs 220-197-9 |
| 4,4'-dihydroxy diphenyl sulfide |
| 4,4'-thiodiphenol, 99% |
| bis(4-oxyphenyl)sulfide |
| 4,4'-sulfanediyldiphenol |
| CHEBI:38957 , |
| D1356 |
| OPREA1_271899 |
| vwgkevwfbouand-uhfffaoysa- |
| 4-(4-hydroxyphenyl)sulfanylphenol |
| inchi=1/c12h10o2s/c13-9-1-5-11(6-2-9)15-12-7-3-10(14)4-8-12/h1-8,13-14h |
| AKOS000120152 |
| STK672128 |
| NCGC00248889-01 |
| unii-ngn288m6mm |
| ngn288m6mm , |
| cas-2664-63-3 |
| dtxsid9047960 , |
| NCGC00258526-01 |
| dtxcid5027936 |
| tox21_200973 |
| A818543 |
| 4-(4-hydroxyphenylthio)phenol |
| FT-0623039 |
| 4,4-dihydroxydiphenyl sulfide |
| AM84852 |
| AB01333629-02 |
| SCHEMBL29726 |
| phenol, p,p'-thiobis- |
| phenol, p,p'-thiodi- |
| 4-hydroxyphenyl sulfide |
| 4,4'-thiobis[phenol] |
| 4-[(4-hydroxyphenyl)sulfanyl]phenol |
| STR04624 |
| F0902-7612 |
| CHEMBL3183502 , |
| 4,4'-dihydroxydiphenyl sulfide;4,4'-thiobisphenol |
| mfcd00002349 |
| J-514035 |
| SR-01000596915-1 |
| sr-01000596915 |
| 4,4`-thiodiphenol |
| a8k , |
| 4,4-thiobis-phenol |
| NCGC00248889-02 |
| 4.4/'-thiodiphenol |
| Q27118057 |
| bdbm50515033 |
| CS-W014789 |
| E83012 |
| EN300-20642 |
| Z104479422 |
| Class | Description |
|---|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 74.4719 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 7.6555 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 18.8426 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 29.0642 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 30.2367 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378; AID1259394 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 53.6932 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 29.2779 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 25.7500 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 30.8907 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 64.1501 | 0.0015 | 30.6073 | 15,848.9004 | AID1224849 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 50.9562 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 26.9661 | 0.0002 | 29.3054 | 16,493.5996 | AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 16.2471 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 36.3135 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 72.8461 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 48.1855 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 24.9066 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 57.1738 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA gyrase subunit A | Escherichia coli K-12 | IC50 (µMol) | 950.0000 | 0.0239 | 0.5629 | 5.2300 | AID1413264 |
| DNA gyrase subunit B | Escherichia coli K-12 | IC50 (µMol) | 950.0000 | 0.0050 | 0.4398 | 5.2300 | AID1413264 |
| Oxysterols receptor LXR-beta | Homo sapiens (human) | Ki | 68.0000 | 0.0022 | 0.0730 | 0.3520 | AID1562690 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1413267 | Inhibition of recombinant Escherichia coli DNA gyrase assessed as reduction of topological transition of relaxed pHTO-1 to its negatively supercoiled form at 1 mM after 30 mins by agarose gel electrophoresis | 2018 | MedChemComm, Oct-01, Volume: 9, Issue:10 | Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes. |
| AID1562690 | Binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) assessed as inhibitory constant incubated for 30 mins by fluorescence polarization binding assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay. |
| AID1820768 | Inhibition of recombinant full length H-RNAase L (1 to 741 residues) expressed in Escherichia coli BL21 (DE3) using 5'-FAM-UAA-UCA-AAU-UCU-UAU-UUG-CCC-CAU-UUU-UUU-GGU-UUA-BHQ-1-3' as substrate incubated for 60 min by FRET assay | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2 | Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery. |
| AID1562692 | Competitive binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) at 1 mM incubated for 30 mins by fluorescence polarization binding assay relative to tracer 1 | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay. |
| AID1820769 | Inhibition of recombinant full length P-RNAase L (1 to 743 residues) expressed in Escherichia coli BL21 (DE3) using 5'-FAM-UAA-UCA-AAU-UCU-UAU-UUG-CCC-CAU-UUU-UUU-GGU-UUA-BHQ-1-3' as substrate incubated for 60 min by FRET assay | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2 | Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery. |
| AID1413264 | Inhibition of full length Escherichia coli DNA gyrase ATPase activity measured for 20 mins by lactate dehydrogenase assay | 2018 | MedChemComm, Oct-01, Volume: 9, Issue:10 | Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes. |
| AID1591599 | Agonist activity at MT1 receptor (unknown origin) expressed in HEK293 cells at 0.5 mM by Fluo-8 dye-based calcium assay relative to control | 2019 | Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15 | Polybenzyls from Gastrodia elata, their agonistic effects on melatonin receptors and structure-activity relationships. |
| AID1124828 | Antagonist activity at human Gal4-fused ER-beta expressed in HEK293 cells assessed as inhibition of 17beta-estradiol-induced effect by luciferase reporter gene assay | 2014 | Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7 | Design and synthesis of silicon-containing steroid sulfatase inhibitors possessing pro-estrogen antagonistic character. |
| AID1591600 | Agonist activity at MT2 receptor (unknown origin) expressed in HEK293 cells at 0.5 mM by Fluo-8 dye-based calcium assay relative to control | 2019 | Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15 | Polybenzyls from Gastrodia elata, their agonistic effects on melatonin receptors and structure-activity relationships. |
| AID1413263 | Inhibition of full length Escherichia coli DNA gyrase ATPase activity at 1 mM measured for 20 mins by lactate dehydrogenase assay relative to control | 2018 | MedChemComm, Oct-01, Volume: 9, Issue:10 | Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes. |
| AID1124822 | Agonist activity at human Gal4-fused ER-alpha expressed in HEK293 cells at 10 uM by luciferase reporter gene assay relative to 17beta-estradiol | 2014 | Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7 | Design and synthesis of silicon-containing steroid sulfatase inhibitors possessing pro-estrogen antagonistic character. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||